Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL...
-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
Next
(38)
•••
Pocketfulofhope
X
Post by
Pocketfulofhope
on May 01, 2025 4:23pm
Nice close
Trending nicely on low volume. Support is moving up with the push. Very nice.. if this gets hit will any level of serious volume it could .. too early to get crazy excited but we are
...more
(38)
•••
Pocketfulofhope
X
Post by
Pocketfulofhope
on Apr 28, 2025 12:32pm
Great news and market is buying
This seems to always trade light but she is trending up. They have recently been involved in investors awareness campaigns so maybe news eyes are liking what we are seeing.
(38)
•••
Pocketfulofhope
X
Post by
Pocketfulofhope
on Apr 01, 2025 11:55am
Interesting news
Could lead to stronger investor awareness and hopefully support.
(38)
•••
Pocketfulofhope
X
Post by
Pocketfulofhope
on Mar 13, 2025 12:17pm
Started a position today.
Looks like she might trend up for a bit.. great luck to all
(123)
•••
ENEMENEMYNEMO
X
Post by
ENEMENEMYNEMO
on Jan 05, 2025 5:35pm
Info for Newbies
https://t.co/bP1YwDIneR
(123)
•••
ENEMENEMYNEMO
X
Post by
ENEMENEMYNEMO
on Jan 05, 2025 5:34pm
JP Morgan Summit
Stay tuned for news on breakthroughs next week!
(5)
•••
badbusiness
X
Comment by
badbusiness
on Dec 06, 2024 11:55am
RE:RE:Medicenna Provides Clinical Update and Announces First Compl
This stock is so undervalued, hidden gem
(61)
•••
windymayor1
X
Comment by
windymayor1
on Dec 05, 2024 11:14am
RE:Medicenna Provides Clinical Update and Announces First Compl
Never a bad announcement. Hope Merck is taking a strong look and crunching #s!
(123)
•••
ENEMENEMYNEMO
X
Post by
ENEMENEMYNEMO
on Nov 09, 2024 4:19pm
SITC NEWS!!!
Mono therapy ORR of 25% (FDA worthy) And Combo therapy 3 SD and one PR already Yipeee MERCK must be sniffing. https://ir.medicenna.com/static-files/aaddc210-ee56-4905
...more
(61)
•••
windymayor1
X
Comment by
windymayor1
on Aug 15, 2024 11:15am
RE:Medicenna Reports First Quarter Fiscal 2025 Financial Result
Nice addition to the board today!
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 27, 2024 8:19am
New Press Release - Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical developmentResults...
read article.
(61)
•••
windymayor1
X
Comment by
windymayor1
on Jun 26, 2024 11:55am
RE:RE:RE:RE:Today's news
Nice recovery above $2.00!
(686)
•••
Galaxym31
X
Comment by
Galaxym31
on Jun 17, 2024 10:15am
RE:RE:RE:Today's news
Not today .
(61)
•••
windymayor1
X
Comment by
windymayor1
on Jun 11, 2024 6:00pm
RE:RE:Today's news
#2 Top % gainer today on TSX
(686)
•••
Galaxym31
X
Comment by
Galaxym31
on Jun 03, 2024 9:24pm
RE:Today's news
Old news still looking for a partner to help fund a p3 trial
Prev
1
2
3
4
5
6
7
8
9
10
11
12
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >